24 / 154
350
chemoradiotherapy for anaplastic oligodendroglioma: long-
term results of RTOG 9402. J Clin Oncol 31:337-43, 2013.
24. Van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant
procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term
follow-up of EORTC brain tumor group study 26951. J Clin
Oncol 31:344-50, 2013.
25. Jiao Y, Killela PJ, Reitman ZJ, et al: Frequent ATRX, CIC, FUBP1
and IDH1 mutations refine the classification of malignant
gliomas. Oncotarget 3:709-22, 2012.
26. Wick W, Platten M, Meisner C, et al: Temozolomide
chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3
trial. Lancet Oncol 13:707-15, 2012.
27. James R. Perry NL, Christopher J. O’Callaghan, et al: A phase
III randomized controlled trial of short-course radiotherapy
with or without concomitant and adjuvant temozolomide
in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC
26062-22061, TROG 08.02, NCT00482677). Presented at
the ASCO Annual Meeting, , Chicago, IL 2016, 2016.
28. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing
and benefit from temozolomide in glioblastoma. N Engl J Med
352:997-1003, 2005.
29. Rapkins RW, Wang F, Nguyen HN, et al: The MGMT promoter
SNP rs16906252 is a risk factor for MGMT methylation in
glioblastoma and is predictive of response to temozolomide.
Neuro Oncol 17:1589-98, 2015.
30. Norden AD, Lesser GJ, Drappatz J, et al: Phase 2 study of dose-
intense temozolomide in recurrent glioblastoma. Neuro Oncol
15:930-5, 2013.
31. Weller M, Tabatabai G, Kastner B, et al: MGMT Promoter
Methylation Is a Strong Prognostic Biomarker for Benefit from
Dose-Intensified Temozolomide Rechallenge in Progressive
Glioblastoma: The DIRECTOR Trial. Clin Cancer Res 21:2057-
64, 2015.
32. Perry JR, Belanger K, Mason WP, et al: Phase II trial of
continuous dose-intense temozolomide in recurrent
malignant glioma: RESCUE study. J Clin Oncol 28:2051-7,
2010.
33. Addeo R, Caraglia M, De Santi MS, et al: A new schedule of
fotemustine in temozolomide-pretreated patients with
relapsing glioblastoma. Journal of Neuro-Oncology 102:417-
424, 2011.
34. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter
methylation status can predict the incidence and outcome
of pseudoprogression after concomitant radiochemotherapy
in newly diagnosed glioblastoma patients. J Clin Oncol
26:2192-7, 2008.
35. Burger PC, Pearl DK, Aldape K, et al: Small cell architecture--a
histological equivalent of EGFR amplification in glioblastoma
multiforme? J Neuropathol Exp Neurol 60:1099-104, 2001.
36. Perry A, Aldape KD, George DH, et al: Small cell astrocytoma:
an aggressive variant that is clinicopathologically and
genetically distinct from anaplastic oligodendroglioma.
Cancer 101:2318-26, 2004.
37. Parker JJ, Dionne KR, Massarwa R, et al: Gefitinib selectively
inhibits tumor cell migration in EGFR-amplified human
glioblastoma. Neuro Oncol 15:1048-57, 2013.
38. Halatsch ME, Schmidt U, Behnke-Mursch J, et al: Epidermal
growth factor receptor inhibition for the treatment of
glioblastoma multiforme and other malignant brain tumours.
Cancer Treat Rev 32:74-89, 2006.
39. Furnari FB, Cloughesy TF, Cavenee WK, et al: Heterogeneity
of epidermal growth factor receptor signalling networks in
glioblastoma. Nat Rev Cancer 15:302-310, 2015.
40. Shinojima N, Tada K, Shiraishi S, et al: Prognostic value
of epidermal growth factor receptor in patients with
glioblastoma multiforme. Cancer Res 63:6962-70, 2003.
41. Huncharek M, Kupelnick B: Epidermal growth factor receptor
gene amplification as a prognostic marker in glioblastoma
multiforme: results of a meta-analysis. Oncol Res 12:107-12,
2000.
42. Gan HK, Cvrljevic AN, Johns TG: The epidermal growth factor
receptor variant III (EGFRvIII): where wild things are altered.
Febs j 280:5350-70, 2013.
43. Choi BD, Archer GE, Mitchell DA, et al: EGFRvIII-targeted
vaccination therapy of malignant glioma. Brain Pathol
19:713-23, 2009.
44. David A. Reardon JS, David Dinh, et al: ReACT: Overall survival
from a randomized phase II study of rindopepimut (CDX-110)
plus bevacizumab in relapsed glioblastoma. Presented at the
ASCO Annual Meeting, Chicago, IL 2015, 2015.
45. Weller M BN, Tran D et al An international, doublt-blind,
phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII
expressing glioblastoma Presented at the SNO 2016,
Scottsdale, AZ.
46. Jones KA, Gilder AS, Lam MS, et al: Selective coexpression
of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells
prevents cellular senescence and contributes to their
aggressive nature. Neuro Oncol 18:667-78, 2016.
47. Kannan K, Inagaki A, Silber J, et al: Whole-exome sequencing
identifies ATRX mutation as a key molecular determinant in
lower-grade glioma. Oncotarget 3:1194-203, 2012.
48. Network TCGAR: Comprehensive, Integrative Genomic Analysis
of Diffuse Lower-Grade Gliomas. New England Journal of
Medicine 372:2481-2498, 2015.
49. Abedalthagafi M, Phillips JJ, Kim GE, et al: The alternative
lengthening of telomere phenotype is significantly associated
with loss of ATRX expression in high-grade pediatric and
adult astrocytomas: a multi-institutional study of 214
astrocytomas. Mod Pathol 26:1425-32, 2013.
50. Wiestler B, Capper D, Holland-Letz T, et al: ATRX loss refines the
classification of anaplastic gliomas and identifies a subgroup
of IDH mutant astrocytic tumors with better prognosis. Acta
Neuropathol 126:443-51, 2013.
51. Schindler G, Capper D, Meyer J, et al: Analysis of BRAF V600E
mutation in 1,320 nervous system tumors reveals high
mutation frequencies in pleomorphic xanthoastrocytoma,
[REV. MED. CLIN. CONDES - 2017; 28(3) 343-351]